What is the recommended empiric treatment for serious Enterococcus faecium infection in adults?

Empiric Treatment for Serious Enterococcus faecium Infection

For serious Enterococcus faecium infections, linezolid 600 mg IV every 12 hours is the recommended first-line empiric therapy, with high-dose daptomycin (8-12 mg/kg/day) as an alternative, particularly for bacteremia. 1

Treatment Algorithm by Clinical Scenario

Bacteremia/Sepsis

• First-line: Linezolid 600 mg IV q12h 1

  • Strong recommendation with demonstrated clinical cure rates of 81.4% and microbiological cure of 86.4% 1
  • Lower mortality (32.8%) compared to daptomycin (35.7%) in comparative data 1

• Alternative: High-dose daptomycin 8-12 mg/kg/day, particularly if:

  • Linezolid contraindicated or unavailable
  • Consider combination with β-lactams (penicillins, cephalosporins, or carbapenems) for enhanced activity 1
  • Critical dosing consideration: For daptomycin-resistant isolates (MIC ≥8 mg/L), doses ≥11 mg/kg show significantly lower mortality (34.4%) versus 8-10 mg/kg (55.1%) 2

Intra-abdominal Infections

• Tigecycline: 100 mg IV loading dose, then 50 mg IV q12h 1
  • Specifically recommended for VRE intra-abdominal infections
  • Duration based on clinical response and source control

Urinary Tract Infections (Uncomplicated)

Choose based on susceptibility when available:

• Fosfomycin: 3 g PO single dose 1
• Nitrofurantoin: 100 mg PO q6h 1
• High-dose ampicillin: 18-30 g IV daily in divided doses (if susceptible) 1
• Amoxicillin: 500 mg PO/IV q8h (if susceptible) 1

Critical Clinical Considerations

Vancomycin Resistance Patterns

E. faecium has dramatically increasing vancomycin resistance rates:

• Up to 45% VRE prevalence in ICU settings 1
• Do not use vancomycin empirically for suspected E. faecium - it is ineffective against VRE and delays appropriate therapy

Species-Specific Resistance

Important distinction: E. faecium shows markedly different resistance patterns than E. faecalis:

• E. faecium: 100% resistance to β-lactams, fluoroquinolones, and fosfomycin in many settings 3
• E. faecalis: Remains largely ampicillin-susceptible (82%) 4
• Empiric therapy must assume E. faecium until species identification confirms otherwise

Monitoring and De-escalation

• Follow-up blood cultures are essential to confirm eradication in bacteremia 5
• Monitor clinical trends and inflammatory markers rather than relying solely on culture timing 5
• For catheter-related BSI: Remove device and consider short-course therapy (<7 days) in uncomplicated cases after source control 5

Common Pitfalls to Avoid

1. Underdosing daptomycin: Using 6 mg/kg (approved for skin infections) instead of 8-12 mg/kg for serious infections results in treatment failure 1

2. Empiric vancomycin use: Given high VRE rates in E. faecium, vancomycin should not be used empirically unless E. faecalis is confirmed 1

3. Inadequate source control: Particularly in intra-abdominal infections, antibiotics alone are insufficient without drainage/surgical intervention 1

4. Prolonged therapy without reassessment: Adjust based on susceptibilities once available; E. faecium may show unexpected ampicillin susceptibility in some cases 4

Treatment Duration

• Bacteremia: Minimum 14 days from first negative blood culture
• Intra-abdominal infection: Based on clinical response and adequate source control 1
• Uncomplicated UTI: 5-7 days typically sufficient
• Complicated infections: Individualize based on site and clinical response

Adverse Effects to Monitor

• Linezolid: Thrombocytopenia (especially >14-21 days), nausea, headache 6
• Daptomycin: Myalgia, elevated CPK, potential nephrotoxicity 4
• Tigecycline: FDA boxed warning regarding increased mortality; use only when alternatives unavailable 7